Myostatin or activin antagonists for the treatment of sarcopenia

摘要

#$%^&*AU2019200082A120190131.pdf#####C:InterwovenNRPortbDCCDAR18267960 1.doex-7/01/2019 ABSTRACT The present invention relates to myostatin or activin antagonists, dose regimen and pharmaceutical compositions thereof, for the treatment of sarcopenia, in particular agerelated sarcopenia. Especially, the myostatin or activin antagonist bimagrumab was found to be beneficial in the treatment of older adults with sarcopenia with respect to increasing their skeletal muscle strength and function. Fig. I :7 100E 0 4 8 10 12 14 16 18 21 Time (Week)